Investigational drug · Phase 2
Cusatuzumab
Also called: OV-1001, JNJ-74494550, ARGX-110
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Leukemia, Myeloid, Acute.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Cusatuzumab"
First trial start
2019
Jul 29, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cusatuzumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leukemia, Myeloid, Acute
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Cusatuzumab" as an intervention, largest first.
- A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyPivotal-lookingActive, not recruiting
OncoVerity, Inc.Industry
NCT06384261 · 140 participants (planned) · Start Jul 22, 2024 · Primary completion Jan 2027
Drug: Cusatuzumab; Venetoclax and 1 more · For: Leukemia, Myeloid, Acute
Sites: Gilbert, Arizona; Duarte, California; Los Angeles, California · 38 sites in all
- A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive ChemotherapyPivotal-lookingActive, not recruiting
OncoVerity, Inc.Industry
NCT04023526 · 103 participants · Start Jul 29, 2019 · Primary completion Aug 15, 2023
Drug: Azacitidine; Cusatuzumab · For: Leukemia, Myeloid, Acute
Sites: Darlinghurst, Australia; Fitzroy, Australia; Melbourne, Australia · 56 sites in all
- Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid LeukemiaActive, not recruiting
OncoVerity, Inc.Industry
NCT04150887 · 61 participants · Start Dec 23, 2019 · Primary completion May 15, 2027
Drug: Cusatuzumab; Azacitidine and 1 more · For: Leukemia, Myeloid, Acute
Sites: Duarte, California; Louisville, Kentucky; Detroit, Michigan · 23 sites in all
OncoVerity, Inc.Industry
NCT03030612 · 38 participants · Start Dec 2016 · Primary completion Aug 2022
Drug: ARGX-110; AZA · For: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Sites: Marseille, France; Paris, France; Pierre-Bénite, France · 7 sites in all
OncoVerity, Inc.Industry
NCT04241549 · 6 participants · Start Mar 25, 2020 · Primary completion Jul 19, 2021
Drug: Cusatuzumab; Azacitidine · For: Leukemia, Myeloid, Acute
Sites: Fukushima, Japan; Maebashi, Japan; Osaka, Japan · 5 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04264806 · 0 participants · Start May 6, 2021 · Primary completion Apr 19, 2022
Drug: Azacitidine; Cusatuzumab · For: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic
Sites: Darlinghurst, Australia; Fitzroy, Australia; Melbourne, Australia · 73 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy.
Li YR, Zhu Y, Yu Y, et al. · Cancer Immunol Res 2026
- Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC.
Zhang M, Wang Z, Gao C, et al. · Int Immunopharmacol 2026
- Targeting leukemia stem cells in unfit acute myeloid leukemia with a CD70-directed third agent: promise and caveats from the ELEVATE trial. Comment on: "Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study".
Lyu T, Zhang Y · Haematologica 2026
- Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.
Roboz GJ, Pabst T, Aribi A, et al. · Haematologica 2026
- CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target.
Forster S, Reinhardt C, Boy M, et al. · Leukemia 2026
- Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.
Sonego B, Ibatici A, Rivoli G, et al. · Cells 2023
Also in development for Leukemia, Myeloid, Acute
- BleximenibJNJ-75276617Phase 32 trials
Johnson & Johnson (Janssen) · Acute Leukemia, Leukemia, Myeloid, Acute
- AG-120Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- AG-221Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- BG1805Phase 21 trial
Guangzhou Bio-gene Technology Co., Ltd · Leukemia, Myeloid, Acute
- TuspetinibHM43239Phase 21 trial
Aptose Biosciences Inc. · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.